PRVA 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• • Revenue was $603.8 million and $480.1 million for the three months ended March 31, 2026 and 2025, respectively;

• • Gross profit was $125.6 million and $103.6 million for the three months ended March 31, 2026 and 2025, respectively;

• • Operating income was $7.4 million and $5.2 million for the three months ended March 31, 2026 and 2025, respectively; and

• • Net income attributable to Privia Health Group, Inc. was $3.1 million and $4.2 million, for the three months ended March 31, 2026 and 2025, respectively.

• • Practice Collections were $914.8 million and $798.6 million for the three months ended March 31, 2026 and 2025, respectively;

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• • Revenue was $580.4 million and $437.9 million for the three months ended September 30, 2025 and 2024, respectively and $1.58 billion and $1.28 billion for the nine months ended September 30, 2025 and 2024, respectively;

• • Gross profit was $122.6 million and $99.9 million for the three months ended September 30, 2025 and 2024, respectively, and $339.0 million and $291.6 million for the nine months ended September 30, 2025 and 2024, respectively;

• • Operating income was $14.4 million and $5.8 million for the three months ended September 30, 2025 and 2024, respectively and $23.0 million and $11.7 million for the nine months ended September 30, 2025 and 2024, respectively; and

• • Net income attributable to Privia Health Group, Inc. was $6.9 million and $3.5 million, for the three months ended September 30, 2025 and 2024, respectively and $13.8 million and $10.0 million for the nine months ended September 30, 2025 and 2024, respectively.

• • Practice Collections were $940.4 million and $739.9 million for the three months ended September 30, 2025 and 2024, respectively and $2.60 billion and $2.18 billion for the nine months ended September 30, 2025 and 2024, respectively;

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• There have been no material changes with respect to this item from the disclosure included in our Annual Report on Form 10-K for the year ended December 31, 2025. For a discussion of our market risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A. of our Annual …

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure to potential changes in inflation or interest rates. We do not hold financial instruments for trading…

• Our primary market risk exposure is changing prime rate-based interest rates. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. Our Credit Agreement bears interest at a b…

• Based on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• investigations may nonetheless impose a significant burden on management and employees and be costly to defend, with unfavorable preliminary or interim rulings.

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• During the first quarter of 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K).

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• On August 22, 2025, Shawn Morris, a member of the Board, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Exchange Act (the “New Morris Plan”). The first possible trade date under the New Morris Plan is Decembe…

• On August 13, 2025, David Mountcastle, the Company’s Chief Financial Officer, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1 of Exchange Act (the “New Mountcastle Plan”). The first possible trade date under the New …